Inactive Instrument

Press Releases MRI Interventions Inc OTC Bulletin Board

Equities

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

ClearPoint Neuro Reports First Quarter 2024 Results	05-07	AQ
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore	05-02	AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	05-02	PR
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators	04-30	AQ
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory	04-29	AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System	04-25	AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System	04-24	AQ
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024	04-23	AQ
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations	04-16	GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	04-08	PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	03-20	AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency	03-19	AQ
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results	03-12	AQ
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System	03-11	AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	03-04	AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	03-01	AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	03-01	AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	02-29	AQ
ClearPoint Neuro Launches Proposed Public Offering of Common Stock	02-28	AQ
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model	02-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MRI Interventions Inc OTC Bulletin Board

Equities

Press Releases

Filters